BONUS ZERTIFIKAT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 15:41:08 2024-06-21 EDT | ||
| 100.2 EUR | +0.62% |
|
| Current month | +5.71% | ||
| 1 month | +5.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 100.3 | +0.68% |
| 24-06-20 | 99.61 | +0.01% |
| 24-06-19 | 99.6 | +0.18% |
| 24-06-18 | 99.42 | +0.26% |
| 24-06-17 | 99.16 | -1.14% |
Real-time Boerse Frankfurt Warrants
Last update June 21, 2024 at 03:41 pm
More quotesStatic data
| Product type | Certificats Bonus |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW9132 |
| ISIN | DE000SW91325 |
| Date issued | 2024-05-08 |
| Strike | 950 kr |
| Maturity | 2024-09-20 (89 Days) |
| Parity | 10 : 1 |
| Emission price | 87.16 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 101.2 € |
|---|---|
| Lowest since issue | 90.34 € |
| Spread | 1.07 € |
| Spread % | 1.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- Certificat
